Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review

References

• Bonkat G, Pickard R, Bartoletti R, Bruyère F, Cai T, Geerlings SE, et al. Guidelines on urological infections. EAU. 2017.
   Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–84.10.1038/nrmicro3432
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–2.10.1093/cid/ciq257
   PubMed Web of Science ®Google Scholar
• Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23(4):320–6.10.1097/QCO.0b013e3283398dc1
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR. Epidemiology and management of emerging drug-resistant Gram-negative bacteria: extended-spectrum β-lactamases and beyond. Urol Clin North Am. 2015;42(4):493–505.10.1016/j.ucl.2015.05.005
   PubMed Web of Science ®Google Scholar
• Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9(5):466–75.10.1016/j.mib.2006.08.011
   PubMed Web of Science ®Google Scholar
• Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection. 1990;18(5):294–8.10.1007/BF01647010
   PubMed Web of Science ®Google Scholar
• Bauernfeind A, Casellas JM, Goldberg M, Holley M, Jungwirth R, Mangold P, et al. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection. 1992;20(3):158–63.10.1007/BF01704610
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014. p. 2015.
   Google Scholar
• Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clin Microbiol Infect. 2012;18(3):253–9.10.1111/j.1469-0691.2011.03550.x
   PubMed Web of Science ®Google Scholar
• Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, et al. Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates. Antimicrob Agents Chemother. 2011;55(8):3917–21.10.1128/AAC.00070-11
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6(11):1335–46.10.3390/ph6111335
   PubMedGoogle Scholar
• Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 2011;66(9):1992–7.10.1093/jac/dkr240
   PubMed Web of Science ®Google Scholar
• Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, et al. Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world. J Clin Microbiol. 2012;50(5):1632–9.10.1128/JCM.06115-11
   PubMed Web of Science ®Google Scholar
• Sheng WH, Badal RE, Hsueh PR, SMART ProGram. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8.10.1128/AAC.00971-12
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–85.10.1016/j.ijantimicag.2016.02.001
   PubMed Web of Science ®Google Scholar
• Mezzatesta ML, La Rosa G, Maugeri G, Zingali T, Caio C, Novelli A, et al. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int J Antimicrob Agents. 2017;49(6):763–6.10.1016/j.ijantimicag.2017.01.020
   PubMed Web of Science ®Google Scholar
• Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015;47(7):1059–66.10.1007/s11255-015-1018-9
   PubMed Web of Science ®Google Scholar
• Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann. 2015;7(1):26–30.10.4103/0974-7796.148585
   PubMed Web of Science ®Google Scholar
• Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. J Coll Physicians Surg Pak. 2014;24(12):914–917.
   PubMed Web of Science ®Google Scholar
• Cagan Aktas S, Gencer S, Batırel A, Hacıseyitoglu D, Ozer S. Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations. Mikrobiyol Bul. 2014;48(4):545–555. [ in Turkish].
   PubMed Web of Science ®Google Scholar
• Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014;42(10):1033–8.10.1016/j.ajic.2014.06.013
   PubMed Web of Science ®Google Scholar
• Kresken M, Pfeifer Y, Hafner D, Wresch R, Korber-Irrgang B. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum beta-lactamases and the role of fosfomycin. Int J Antimicrob Agents. 2014;44(4):295–300.10.1016/j.ijantimicag.2014.05.020
   PubMed Web of Science ®Google Scholar
• Seo MR, Kim SJ, Kim Y, Kim J, Choi TY, Kang JO, et al. Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea. J Korean Med Sci. 2014;29(8):1178–1181.10.3346/jkms.2014.29.8.1178
   PubMed Web of Science ®Google Scholar
• Villar HE, Jugo MB, Macan A, Visser M, Hidalgo M, Maccallini GC. Frequency and antibiotic susceptibility patterns of urinary pathogens in male outpatients in Argentina. J Infect Dev Ctries. 2014;8(6):699–704.
   PubMed Web of Science ®Google Scholar
• Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum beta-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians. 2013;5(2):90–93.10.4103/0974-2727.119849
   PubMedGoogle Scholar
• Lai B, Zheng B, Li Y, Zhu S, Tong Z. In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004–2012). BMC Infect Dis. 2014;14:66.10.1186/1471-2334-14-66
   PubMed Web of Science ®Google Scholar
• Qiao LD, Chen S, Yang Y, Zhang K, Zheng B, Guo HF, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open. 2013;3(12):e004152.10.1136/bmjopen-2013-004152
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Denisuik AJ, Lagace-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, et al. In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. Antimicrob Agents Chemother. 2014;58(2):1252–6.10.1128/AAC.02399-13
   PubMed Web of Science ®Google Scholar
• Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013;17(11):e966–70.10.1016/j.ijid.2013.04.005
   PubMed Web of Science ®Google Scholar
• Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, Falagas ME. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol. 2013;8(5):675–80.10.2217/fmb.13.31
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial C, Rodríguez-Avial I, Hernández E, Picazo JJ. Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005–2009–2011). Rev Esp Quimioter. 2013;26(1):43–46. [in Spanish].
   PubMed Web of Science ®Google Scholar
• Fournier D, Chirouze C, Leroy J, Cholley P, Talon D, Plésiat P, et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect. 2013;43(2):62–6.10.1016/j.medmal.2013.01.006
   PubMed Web of Science ®Google Scholar
• Bonkat G, Muller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013;31:1427–32.10.1007/s00345-013-1031-5
   PubMed Web of Science ®Google Scholar
• Araj GF, Jaber FA. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. J Med Liban. 2012;60(3):142–147.
   PubMedGoogle Scholar
• Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891–6.10.1111/ijcp.2012.66.issue-9
   PubMed Web of Science ®Google Scholar
• Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333–40.10.1007/s15010-011-0132-6
   PubMed Web of Science ®Google Scholar
• Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 2011;44(5):364–8.10.1016/j.jmii.2010.08.012
   PubMedGoogle Scholar
• den Heijer CD, Donker GA, Maes J, Stobberingh EE. Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother. 2010;65(10):2128–33.10.1093/jac/dkq286
   PubMed Web of Science ®Google Scholar
• Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54(9):4006–8.10.1128/AAC.01760-09
   PubMed Web of Science ®Google Scholar
• Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of Fosfomycin Resistance among CTX-M-Producing Escherichia coli Clinical Isolates in Japan and Identification of Novel Plasmid-Mediated Fosfomycin-Modifying Enzymes. Antimicrob Agents Chemother. 2010;54(7):3061–4.10.1128/AAC.01834-09
   PubMed Web of Science ®Google Scholar
• Tena D, González-Praetorius A, González JC, Heredero E, Illescas S, de Baranda CS, et al. Changes in the antimicrobial susceptibility of Escherichia coli isolates from community diagnosed urinary tract infections during the period 2003–2007. Multicentre study in Castilla la Mancha (Spain). Rev Esp Quimioter. 2010;23(1):36–42 . [in Spanish].
   PubMed Web of Science ®Google Scholar
• Chislett RJ, White G, Hills T, Turner DP. Fosfomycin susceptibility among extended-spectrum-beta-lactamase-producing Escherichia coli in Nottingham UK. J Antimicrob Chemother. 2010;65(5):1076–7.10.1093/jac/dkq051
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Peirano G, Pitout JD. The Role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28(3):565–91.10.1128/CMR.00116-14
   PubMed Web of Science ®Google Scholar
• Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C, et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother. 2008;61(5):1024–8.10.1093/jac/dkn084
   PubMed Web of Science ®Google Scholar
• Lavigne JP, Vergunst AC, Goret L, Sotto A, Combescure C, Blanco J, et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS ONE. 2012;7(3):e34294.10.1371/journal.pone.0034294
   PubMed Web of Science ®Google Scholar
• Hussain A, Ewers C, Nandanwar N, Guenther S, Jadhav S, Wieler LH, et al. Multiresistant uropathogenic Escherichia coli from a region in India where urinary tract infections are endemic: genotypic and phenotypic characteristics of sequence type 131 isolates of the CTX-M-15 extended-spectrum-β-lactamase-producing lineage. Antimicrob Agents Chemother. 2012;56(12):6358–65.10.1128/AAC.01099-12
   PubMed Web of Science ®Google Scholar
• López-Cerero L, Navarro MD, Bellido M, Martín-Peña A, Viñas L, Cisneros JM, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother. 2014;69(3):809–14.10.1093/jac/dkt405
   PubMed Web of Science ®Google Scholar
• Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64(4):712–7.10.1093/jac/dkp288
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med. 2010;362(19):1804–13.10.1056/NEJMra0904124
   PubMed Web of Science ®Google Scholar
• Carrër A, Nordmann P. CTX-M-15-producing Klebsiella pneumoniae: a change in the epidemiology of ESBL. Pathol Biol (Paris). 2011;59(6):e133–5.
   PubMedGoogle Scholar
• Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6):315–7.10.1007/BF01641355
   PubMed Web of Science ®Google Scholar
• Livermore DM, Hawkey PM. CTX-M changing the face of ESBLs in the UK. J Antimicrob Chemother. 2005;56(3):451–4.10.1093/jac/dki239
   PubMed Web of Science ®Google Scholar
• Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, Amicosante G, et al. CTX-M type ESBL in Italy: molecular epidemiology of an emerging countryside problem. Antimicrob Agents Chemother. 2006;50(8):2700–6.10.1128/AAC.00068-06
   PubMed Web of Science ®Google Scholar
• Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A, Spanish Group for Nosocomial Infections (GEIH). Nationwide study of E. coli and K. pneumoniae producing ESBL in Spain. Antimicrob Agents Chemother. 2005:49(5):2122–2215.
   Google Scholar
• Poirel L, Bonnin RA, Nordmann P. Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect Genet Evol. 2012;12(5):883–93.10.1016/j.meegid.2012.02.008
   PubMed Web of Science ®Google Scholar
• Younes A, Hamouda A, Dave J, Amyes S. Prevalence of transferable blaCTX-M-15 from hospital-and community-acquired Klebsiella pneumoniae isolates in Scotland. J Antimicrob Chemother. 2011;66(2):313–8.10.1093/jac/dkq453
   PubMed Web of Science ®Google Scholar
• Coelho A, Mirelis B, Alonso-Tarrés C, Larrosa MN, Miró E, Abad RC, et al. Detection of three stable genetic clones of CTX-M-15-producing Klebsiella pneumoniae in the Barcelona metropolitan area Spain. J Antimicrob Chemother. 2009;64(4):862–4.10.1093/jac/dkp264
   PubMed Web of Science ®Google Scholar
• Coelho A, González-López JJ, Miró E, Alonso-Tarrés C, Mirelis B, Larrosa MN, et al. Characterisation of the CTX-M-15-encoding gene in Klebsiella pneumoniae strains from the Barcelona metropolitan area: plasmid diversity and chromosomal integration. Int J Antimicrob Agents. 2010;36(1):73–8.10.1016/j.ijantimicag.2010.03.005
   PubMed Web of Science ®Google Scholar
• Mshana SE, Fritzenwanker M, Falgenhauer L, Domann E, Hain T, Chakraborty T, et al. Molecular epidemiology and characterization of an outbreak causing Klebsiella pneumoniae clone carrying chromosomally located bla(CTX-M-15) at a German University-Hospital. BMC Microbiol. 2015;15:122.10.1186/s12866-015-0460-2
   PubMed Web of Science ®Google Scholar
• Alibi S, Ferjani A, Boukadida J. Molecular characterization of extended spectrum beta-lactamases produced by Klebsiella pneumoniae clinical strains from a Tunisian Hospital. Med Mal Infect. 2015;45(4):139–43.10.1016/j.medmal.2015.01.010
   PubMed Web of Science ®Google Scholar
• Kopacz J, Mariano N, Colon-Urban R, Sychangco P, Wehbeh W, Segal-Maurer S, et al. Identification of extended-spectrum-beta-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M beta-lactamases in non hospitalized patients. Antimicrob Agents Chemother. 2013;57(10):5166–9.10.1128/AAC.00043-13
   PubMed Web of Science ®Google Scholar
• Morfín-Otero R, Mendoza-Olazarán S, Silva-Sánchez J, Rodríguez-Noriega E, Laca-Díaz J, Tinoco-Carrillo P, et al. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum beta-lactamase. Microb Drug Resist. 2013;19(5):378–83.10.1089/mdr.2012.0263
   PubMed Web of Science ®Google Scholar